# Adjunctive Multicomponent Crystals of Two Anti-Tubercular Drugs with Pyridoxine

## TL;DR

This paper explores combining anti-tuberculosis drugs with pyridoxine to improve treatment and reduce side effects.

## Contribution

The study introduces new drug-vitamin combinations as potential improved treatment regimens for tuberculosis.

## Key findings

- Two multicomponent salts containing pyridoxine were successfully isolated and characterized.
- Mechanochemistry proved efficient for preparing cocrystals of the drug-vitamin combinations.
- The combinations may lead to better therapeutic outcomes and fewer adverse effects in TB treatment.

## Abstract

Background/Objectives: Cocrystallisation is a well-established path for altering the physicochemical properties and bioavailability of active pharmaceutical ingredients (APIs). A common side effect of anti-tubercular medicines is the depletion of group B vitamin reserves in TB patients. Co-administration of supplements such as pyridoxine (vitamin B6) during TB therapy may be used to ameliorate the harmful side effects of vitamin B6 deficiency. Methods: Mechanochemical grinding and solvent evaporation experiments using pyridoxine (PN) with 4-aminosalicylic acid (PAS) and separately with pyrazinecarboxylic acid (PCBA) were conducted. The bulk powder and crystal analysis was performed using FTIR, PXRD, DSC, TGA and SCXRD. Results: The isolation and characterization of two multicomponent salts containing pyridoxine, i.e., PN-PAS·H2O and PN-PCBA, were completed. Mechanochemistry is an efficient method for the preparation of cocrystals. Conclusions: The drug–vitamin combinations may be useful for the development of new treatment regimens with potentially improved therapeutic outcomes and reduced adverse effects.